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Abstract
Background: An 11-valent pneumococcal conjugate vaccine could provide significantly larger
reduction in pneumococcal disease burden than the currently available 7-valent vaccine formulation
in many countries.
Methods: In total, 50 infants were enrolled to this open, uncontrolled study, which evaluated the
safety and immunogenicity of an aluminium adjuvanted 11-valent mixed-carrier diphtheria toxoid
or tetanus protein-conjugated vaccine (11-PncTD) when administered in three doses at 6, 10 and
14 weeks of age simultaneously with DTwP//PRP-T and OPV vaccines in Filipino infants.
Results: The rates of local reactions between the two injection sites, those associated with the
11-PncTD vaccine and those with the DTwP//PRP-T were almost of equal frequency for all three
vaccine doses except for induration, which was significantly more common in the DTP//PRP-T
injection site. Fever was present in 39%, 22% and 21% of infants following each of the three doses.
Antibody responses were determined by an enzyme immunoassay method before the first
vaccination and after the three doses. The vaccine elicited a significant anti-pneumococcal
polysaccharide antibody response against all serotypes included in the vaccine, except for type 14,
for which the pre-vaccination geometric mean antibody concentration (GMC) was high (1.61 µg/
ml). The GMCs one month after the vaccination series ranged from 1.1 micrograms/ml for type 6B
to 23.4 µg/ml for type 4.
Conclusion: The 11-PncTD vaccine is safe, well-tolerated and immunogenic. The effectiveness of
the non-adjuvanted formulation of the vaccine in preventing pneumonia is currently being evaluated
in the Philippines.
Background
Infections caused by Streptococcus pneumoniae (pneumo-
coccus) are responsible for over 1 million deaths among
children less than 5 years of age in developing countries
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[1]. This estimate of pneumococcal disease burden may
be an underestimate as the aetiology of pneumonia, the
most common of severe infections is difficult to assess [2].
Two studies, which reported 97.4% (95% CI 82.7, 99.9%)
[3] and 76.8% (95% CI -9.4, 95.1%) [O'Brien, personal
communication] efficacy against serotypes included in the
vaccine, and the post-licensure surveillance [4] have
shown that the seven-valent pneumococcal conjugate vac-
cine (Prevenar®) prevents majority of invasive pneumo-
coccal disease in children. The vaccine also prevented
20.5% (95% CI 4.4, 34.0%) of radiologically confirmed
pneumonia [5] and 57 % (95%CI 44, 67%) of acute otitis
media episodes caused by the vaccine serotypes [6]. The
vaccine is primarily developed for the U.S. and European
epidemiological situation, and it has only a limited cover-
age of serotypes causing serious pneumococcal infections
in most developing countries. In Asia, for example, the
coverage of serotypes causing invasive pneumococcal
infections among young children is less than 50% [7]. The
vaccine formulations with capsular polysaccharides of 11
pneumococcal serotypes could provide nearly 80% sero-
type coverage in most countries being thus justified for
global use [7].
This report describes a safety and immunogenicity study
of an aluminium adjuvanted eleven-valent mixed carrier
diphtheria toxoid and tetanus protein-conjugated pneu-
mococcal vaccine in Filipino infants. The study preceded
a large-scale study, started in July 2000 in the Philippines,
in which the effectiveness of the non-adjuvanted formula-
tion of the vaccine is evaluated in prevention of radiolog-
ically confirmed pneumonia in children.
Methods
Study subjects
From June 1998 to August 1999, all infants born at full
term of pregnancy (≥ 37 weeks) and aged 6 to 9 weeks,
who were to start their national vaccination program,
were offered enrolment to the open, uncontrolled,
descriptive study at the village health centre in Cabuyao, a
semi-urban municipality of Laguna, Island of Luzon, the
Philippines. Written informed consent was obtained from
the guardians of the study children. The study was
approved by the Ethical and Institutional Review Board of
the Research Institute for Tropical Medicine (RITM),
Manila, the Philippines. The study was conducted in com-
pliance with the Helsinki Declaration.
Vaccines and immunization schedule
The study vaccine (lot # S 3497; Aventis Pasteur, Lyon,
France) included pneumococcal PS of serotypes 3, 6B, 14
and 18C coupled to diphtheria toxoid protein and pneu-
mococcal PS of serotypes 1, 4, 5, 7F, 9V, 19F and 23F cou-
pled to tetanus protein. The vaccine was formulated with
aluminium hydroxide as an adjuvant. It contained 1 µg/
dose of PS type 1, 4, 5, 7F, 9V, 19F and 23F, 3 µg/dose of
PS type 3, 14 and 18C, and 10 µg/dose of type 6B.
The concomitant vaccines used included diphtheria, teta-
nus, whole-cell pertussis and Haemophilus influenzae type
b (DTwP//PRP-T, Aventis Pasteur, France), oral poliovirus
(OPV, Aventis Pasteur, France) and plasma-derived hepa-
titis B vaccine (Med Test, Korea).
The study vaccine for intramuscular injection was pre-
sented in a pre-filled (0.5 ml) ready-to-use glass syringe.
The vaccine was administered by the deep intramuscular
route into the anterolateral aspect of the right thigh. The
DTwP//PRP-T vaccine was administered in the opposite
thigh and the hepatitis B vaccine in the deltoid area of the
left arm. The three doses of study vaccine were given
simultaneously with the concomitant vaccines according
to the Expanded Program on Immunisation (EPI) sched-
ule at 6, 10 and 14 weeks of age.
Three ml of blood was collected by venipuncture before
the vaccination at 6 weeks of age and after three doses at
18 weeks of age. Blood samples were allowed to clot from
30 minutes to 2 hours at room temperature and then cen-
trifuged. Serum samples were stored at the RITM labora-
tory at -20°C until transported on dry ice to Helsinki,
Finland for analysis.
Safety evaluation
Each infant was observed for 30 minutes after the injec-
tion for any immediate vaccine related reactions. A digital
thermometer was supplied to parents to measure infants'
rectal temperature. Local reactions such as induration,
redness and swelling were measured by a plastic calliper.
Fever was defined as rectal temperature ≥ 38°C whereas
the local reactions were considered significant if measured
> 2 cm. The parents or guardians were asked to record
local and systemic reactions in the evening of the vaccina-
tion day (approximately 8 hours after injection) and in
the morning of the first to fifth day post-vaccination. The
safety surveillance data was then collected by study per-
sonnel and entered to database. A serious adverse event
was defined as any untoward medical occurrence that at
any dose resulted in death, was life-threatening, required
inpatient hospitalisation or prolongation of existing hos-
pitalisation, resulted in persistent or significant disability/
incapacity, or was a congenital anomaly/birth defect. All
such events were followed up and reported by the study
personnel.
Immunogenicity of the vaccine
A standardised enzyme immunoassay (EIA) was used to
quantify the serum IgG antibodies to capsular polysaccha-
rides of each of the eleven serotypes [8]. The EIA resultsBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/17
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were expressed as micrograms/ml calculated based on the
assigned IgG values of the 89 – SF2 reference serum from
Food and Drug Administration (Bethesda, MD, USA). The
detection limits (µg/ml) for each serotypes were: sero-
types 1(0.1), 3, 4,18C (0.07), 5(0.15), 6B and 23F (0.09),
7F, 9V (0.08), 14 (0.14) and 19F (0.7), respectively. The
assay was performed at the Vaccine immunology labora-
tory of the National Public Health Institute (KTL), Hel-
sinki, Finland. The detailed serotype specific antibody
responses following each of the vaccine doses have been
published earlier [9].
Statistical Methods
Immunogenicity results are given as geometric mean con-
centrations (GMCs) of antibodies, proportions of infants
with over 2- and 4-fold increases between different series,
and as proportion of children achieving a predefined cut
off value of ≥1.0 µg/ml of antibodies concentration. Anti-
body values under the detection limit for each serotype
were given an arbitrary value, half of the detection limit.
Statistical comparisons to test the hypothesis of equal
GMCs were made with paired t-test using log-transformed
data. Fisher's exact test was used for comparison of local
reactions associated with EPI and study vaccine injection
sites. Chi square test was used to analyse the rates of sys-
temic reactions after each vaccine dose. The level of signif-
icance was set at p < 0.05.
Results
In total, 47 of the 50 infants enrolled to the study com-
pleted the primary series of three vaccine doses. Serum
sample was available from 49 infants before and from 47
after the three vaccine doses. The reasons for withdrawal
included: parental request (1) and transfer of residence
(1). One infant did not continue vaccination series due to
a hypotonic hyporesponsive episode following
immunization.
There were 28 boys (56%) and 23 girls (44%). The mean
ages of infants at each vaccination visit were 7.1 weeks
(range: 6–8 weeks) at dose 1; 11.2 weeks (range: 10–13
weeks) at dose 2; 15.6 weeks (range: 14–18 weeks) at dose
3 and 19.5 weeks (range 18–23 weeks) on the fourth visit
when the post vaccination serum sample was collected.
The most common local reactions in the order of fre-
quency were induration, pain, swelling and redness
(Table 1). The rate of local reactions between the two
injection sites, those associated with the study vaccine and
the DTwP//PRP-T vaccine were almost of equal frequency
following each of the three doses, except for induration.
The rate of induration was significantly more common
after all of the three doses in the DTwP//PRP-T vaccine
than the study vaccine: following dose 1 (45.1 % vs. 8.0
%, p < 0.001); dose 2 (30.6 % vs. 10.2 %, p < 0.01) and
dose 3 (19.1% vs. 4.2%, p < 0.02).
The clinical parameters included in the evaluation of sys-
temic events after each dose included fever, vomiting,
diarrhoea, inconsolable crying, unusual drowsiness, irrita-
bility, anorexia and insomnia (Table 2). The rate of fever
(≥ 38°C) after each of the three doses were 39.2%, 22.4%
and 21.3%. Fever of 38.7°C or more occurred at 8.0 %,
12.2% and 8.5% of the infants. All local and systemic
reactions resolved without medical intervention. There
was a trend in the frequency of both local and systemic
reactions to decrease with successive doses of vaccine.
There were nine serious adverse events, which consisted of
eight hospitalisations. The reasons included: one case of
suspected meningitis, 2 cases of acute gastroenteritis, 3
cases of bronchopneumonia, one case of bronchitis and
one urinary tract infection. The patient with suspected
meningitis had received immunization 17 days before the
onset of fever and convulsions, which led to death very
soon after admission to hospital. The aetiology of infec-
tion remained unconfirmed. All these adverse events were
reported as not related to the study vaccine by the investi-
gators. There was one hypotensive hyporesponsive epi-
sode that occurred 20 minutes after administration of 11-
PncTD and DTwP//PRP-T vaccines. The episode resolved
within 15 minutes and was considered as probably study
vaccine related. Another case of cyanosis of the lips and
nails, fever and chills was reported the day of the third vac-
cination and was considered as probably related to the
vaccination by investigators. At follow-up, this event was
re-evaluated as being non-serious. The investigator
decided however to withdraw the subject from the study.
The GMCs of antibodies before and after three vaccine
doses of the 11-PncTD vaccine are summarised in Table 3.
The pre-vaccination GMCs at 6 weeks of age varied
between 0.27 µg/ml for serotype 4 and 1.61 µg/ml for
type 14. After three vaccine doses, all GMCs of antibodies,
except for serotype 14 (p = .253) were significantly higher
than before the vaccination series. At 18 weeks, all infants
had antibody concentration > 1.0 µg/ml against serotypes
1, 3, 4, 5, 7F, 9V, and 19F whereas 49, 83, 91.5 and 87.2
% of infants had concentration > 1.0 µg/ml against sero-
types 6B, 14, 18C, and 23F, respectively.
Discussion
A new vaccine should have a protective immunogenicity
and an acceptable safety profile similar to present child-
hood vaccines. The results of our study suggests that
immunisation with three doses of 11-PncTD vaccine is
safe, well-tolerated and immunogenic in infants. This is in
agreement with other studies with the 11-PncTD vaccineBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/17
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formulations [10,11] [In Iceland Sigurdardottir, personal
communication and in Chile Lagos, personal communi-
cation] and with other pneumococcal conjugate vaccines
[3,6,12,13].
No significant safety problems have been reported in
safety and immunogenicity studies, in which over 20 000
subjects received various number of doses of different
pneumococcal vaccine candidates [14,15]. Although the
lack of standard definitions for different clinical signs and
symptoms may bias the comparison of safety profiles of
different pneumococcal vaccines, the local reactions such
as redness, swelling, induration and pain at the site of
injection have been the most commonly reported adverse
effects. The rate of local reactions has varied between 6
and 38% in different studies, but, as observed also in this
study, has been lower at the pneumococcal than at the
DTP-Hib vaccine site [3,6,11,16].
The 11-PncTD vaccine formulation used in this study con-
tained aluminium adjuvant, which has been associated
with increased local reactions [17]. In Israel and Finland
the non-adjuvanted 11-PncTD formulation was less fre-
quently associated with local reactions than the adjuvan-
Table 1: Local reactions (%) within the first 5 days after vaccination in infants receiving three doses of DTwP//PRP-T, OPV, hepatitis B 
and the 11PncTD conjugate vaccines
Reaction Dose 1 Dose 2 Dose 3
DTP 11-PncTD DTP 11-PncTD DTP 11-PncTD
Local reactions 64.7 41.4 42.9 26.5 34.0 23.4
Induration 45.1 7.8 30.6 10.2 19.1 4.3
Pain 45.1 27.5 30.6 22.4 23.4 21.3
Redness 7.8 0 2.0 0 2.1 0
Swelling 15.7 7.8 6.1 4.1 0 0
Vaccine administered at 6 (N = 50), 10 (N= 49) and 14 (N= 47) weeks of age
Table 2: Systemic reactions (%) within the first 5 days after vaccination in infants receiving three doses of DTwP//PRP-T, OPV, hepatitis 
B and the 11PncTD conjugate vaccines
Reaction Dose 1 Dose 2 Dose 3
All systemic 80.4 53.1 46.8
Fever 40.0 22.3 21.3
Vomiting 4.0 2.0 4.3
Diarrhoea 10.0 6.2 10.6
Inconsolable crying 34.0 28.6 14.9
Unusual drowsiness 16.0 2.0 2.1
Irritability 44.0 24.5 10.6
Anorexia 14.0 8.2 6.4
Insomnia 36.0 12.2 10.6
Vaccine administered at 6 (N = 50), 10 (N= 49) and 14 (N= 47) weeks of age
Table 3: Geometric mean concentration (GMC, µg /ml) and 95 % confidence intervals (CI) of antibodies against pneumococcal serotypes 
included in the 11-valent pneumococcal vaccine given at 6, 10 and 14 weeks of age in Filipino infants
A g e 1345 6 B 7 F 9 V 1 4 1 8 C 1 9 F 2 3 F
6 wk
(n = 49)
0.48
(0.34–0.68)
0.40
(0.30–0.54)
0.27
(0.19–0.38)
0.53
(0.37–0.77)
0.33
(0.24–0.46)
0.80
(0.58–1.12)
0.53
(0.39–0.77)
1.54
(1.03–2.53)
0.38
(0.26–0.52)
0.96
(0.64–1.45
0.49
(0.35–0.73)
18 wk
(n = 47)
15.23
(12.75–18.19)
4.87
(3.91–6.08)
23.41
(18.95–28.92)
12.49
(10.77–14.48)
1.12
(0.77–1.61)
8.87
(6.82–11.53)
7.69
(6.27–9.43)
2.18
(1.65–2.87)
4.50
(3.18–6.38)
16.11
(12.81–20.24)
3.89
(2.83–5.34)
Serum sample withdrawn before vaccination at 6 weeks of age and 4 weeks after the third dose at 18 weeks of ageBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/17
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ted vaccine formulation [10,11]. This, together with the
general development towards aluminium-free vaccines
despite the acceptable safety of aluminium adjuvants over
past six decades [18], led to the decision of selecting the
non-adjuvanted 11-PncTD for the on-going effectiveness
study.
In this study, fever was the most commonly noted sys-
temic adverse effect following immunization. The rate
between 39% and 21%, depending on the number of the
dose, is similar to other studies, where fever above 38.5 C
has been reported in up to 52% of children, 22 % in tod-
dlers and 4% in adults [14]. As this study did not include
a control group with no pneumococcal vaccination given
it is difficult to estimate if the 11PncTD increased the rate
of systemic reactions when compared to infants receiving
only EPI vaccines. Whether the one hypotensive hypore-
sponsive episode noted in this study was due to 11-PncTD
vaccine or other concomitantly administered vaccines is
difficult to determine. The other serious adverse events
reported were unlikely to have a causal relationship with
the 11-PncTD vaccine.
The 11PncTD vaccine elicited high antibody responses in
Filipino infants. The antibodies at 6 weeks of age were
most likely passively transferred maternal antibodies. The
GMCs of antibodies against several serotypes such as 7F,
14 and 19F were considerably high at 6 weeks, but the
detailed analysis of antibody responses to each vaccine
dose did not support the hypothesis of interference in
immune response due to pre-existing antibodies [9].
The GMCs following three doses of vaccination against
most pneumococcal serotypes with the exception of types
6B and 14 were higher than described in infants receiving
other pneumococcal conjugate vaccines in other popula-
tions [3,6,19] or in Finnish and Israeli infants [10] or tod-
dlers [11] receiving the same vaccine. The causes for this
variation among populations are unknown yet, and may
include reasons such as in-utero priming due to maternal
vaccination with tetanus toxoid, boosting effect of early
pneumococcal carriage common in developing countries,
age at immunization, genetic factors and other concomi-
tant vaccines. This study did not evaluate the immuno-
genicity of other concomitantly administered vaccines.
However, another safety and immunogenicity study con-
ducted in the Philippines with the same vaccine did not
demonstrate significant interference between different
vaccine antigens [Biltoft, personal communication].
Both quality and quantity of serotype specific antibodies
are important characteristics of immunogenicity of pneu-
mococcal conjugate vaccines. In this study, majority of
infants had antibody concentration ≥ 1.0 µg/ml against
the eleven serotypes included in the vaccine. Without
established serologic correlates of protection against
pneumococcal diseases, the actual impact of the 11-
PncDT vaccine in reducing pneumococcal specific disease
burden is difficult to estimate [19]. When the vaccine is
administered simultaneously with the whole-cell pertus-
sis containing DTP-vaccine, the similar or higher post-
immunisation GMCs of antibodies compared to those
achieved in the U.S. with the 7-valent vaccine suggest,
however that the efficacy could be at least similar. Further-
more, pneumococcal conjugate vaccines, like the Hib con-
jugates evoke a T-cell dependent immune response, which
leads to formation of immunologic memory [20,21].
This, combined with the herd immunity effect achieved
through reduced circulation of pneumococci due to lower
carriage acquisition of vaccine serotypes [22], may further
increase the effectiveness of the pneumococcal conjugate
vaccines.
Conclusions
The 11-PncTD vaccine is safe, well-tolerated and immu-
nogenic in infants. The effectiveness of the non-adjuvan-
ted formulation of the vaccine in prevention of
pneumonia is currently being evaluated in the Philip-
pines. The availability and routine use of pneumococcal
conjugate vaccines might have a very significant public
health impact in developing countries where the pneumo-
coccal infections are a major cause for childhood
mortality.
Competing interests
H Käyhty has provided consultancies on advisory boards
for Aventis Pasteur and GlaxoSmithKline; has had travel
paid for by Aventis Pasteur, GlaxoSmithKline, Spectrum
Medical Sciences and Wyeth Lederle Vaccines as an invited
speaker or expert at symposia; and has received honoraria
from Aventis Pasteur, GlaxoSmithKline, and Wyeth Led-
erle Vaccines. The other authors declare no competing
interests.
Authors' contributions
MRZC analysed the safety and TP immunogenicity data.
CPG was the study physician responsible for enrolment
and evaluation of study subjects. HK supervised the
immunogenicity analysis and participated in the planning
of study design together with MGL, who was the principal
investigator and HN, who was the study coordinator. All
authors contributed to the writing of the manuscript and
approved the final version.
Acknowledgements
This ARIVAC research consortium study was supported by EU / INCO 
DC: International Cooperation with Developing Countries, contract num-
bers: ERBIC18CT970219 and ICA4-CT-1999-10008EU. We thank the fam-
ilies in the Cabuyao community as well as clinical and laboratory staff and 
statisticians of the Research Institute for Tropical Medicine, National Public 
Health Institute and Aventis Pasteur.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/17
Page 6 of 6
(page number not for citation purposes)
References
1. Mulholland K: Strategies for the control of pneumococcal
diseases. Vaccine 1999, 17(Suppl 1):S79-84.
2. Vuori-Holopainen E, Salo E and Saxen H et al.: Etiological diagnosis
of childhood pneumonia by use of transthoracic needle aspi-
ration and modern microbiological methods.  Clin Infect Dis
2002, 34:583-590.
3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L,
Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Koh-
berger R, Watson W, Austrian R and Edwards K: Efficacy, safety
and immunogenicity of heptavalent pneumococcal conju-
gate vaccine in children. Northern California Kaiser Perma-
nente Vaccine Study Center Group [see comments]. Pediatr
Infect Dis J 2000, 19:187-195.
4. Black S, Shinefield H, Hansen J, Elvin L, Laufer D and Malinoski F:
Postlicensure evaluation of the effectiveness of seven valent
pneumococcal conjugate vaccine.  Pediatric Infectious Diseases
Journal 2001, 20:1105-1107.
5. Black SB, Shinefield H and Ling S et al.: Effectiveness of heptava-
lent pneumococcal conjugate vaccine in children younger
than five years of age for prevention of pneumonia. Pediatric
Infectious Diseases Journal 2002, 21:810-816.
6. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A,
Kayhty H, Karma P, Kohberger R, Siber G and Makela PH: Efficacy
of a pneumococcal conjugate vaccine against acute otitis
media. N Engl J Med 2001, 344:403-409.
7. Hausdorff WP, Bryant J, Paradiso PR and Siber GR: Which pneumo-
coccal serogroups cause the most invasive disease: implica-
tions for conjugate vaccine formulation and use, part I. Clin
Infect Dis 2000, 30:100-121.
8. Kayhty H, Ahman H, Ronnberg PR, Tillikainen R and Eskola J: Pneu-
mococcal polysaccharide-meningococcal outer membrane
protein complex conjugate vaccine is immunogenic in
infants and children. J Infect Dis 1995, 172:1273-1278.
9. Puumalainen T, Zeta-Capeding MR, Kayhty H, Lucero M, Auranen K,
Leroy O and Nohynek H: Antibody response to an eleven-
valent pneumococcal connjugate vaccine in Filipino infants.
Pediatr Infect Dis J 2002, 21:309-314.
10. Wuorimaa T, Dagan R and Vakevainen M et al.: Avidity and sub-
class of IgG after immunization of infants with an 11-valent
pneumococcal conjugate vaccine with and without alumin-
ium adjuvant. J Infect Dis 2001, 184:1211-1215.
11. Wuorimaa T, Dagan R, Eskola J, Janco J, Ahman H, Leroy O and Kay-
hty H: Tolerability and immunogenicity of an eleven-valent
pneumococcal conjugate vaccine in healthy toddlers. Pediatr
Infect Dis J 2001, 20:272-277.
12. Miernyk KM, Parkinson AJ, Rudolph KM, Petersen KM, Bulkow LR,
Greenberg DP, Ward JI, Brenneman G, Reid R and Santosham M:
Immunogenicity of a heptavalent pneumococcal conjugate
vaccine in apache and navajo indian, alaska native, and non-
native american children aged <2 years [In Process
Citation]. Clin Infect Dis 2000, 31:34-41.
13. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I and Klugman
KP: mmunogenicity and impact on nasopharyngeal carriage
of a nonavalent pneumococcal conjugate vaccine. J Infect Dis
1999, 180:I1171-1176.
14. Wuorimaa T and Kayhty H: Current state of pneumococcal
vaccines. Scand J Immunol 2002:56.
15. Eskola J and Anttila M: Pneumococcal conjugate vaccines. Pediatr
Infect Dis J 1999, 18:543-551.
16. Wuorimaa T, Kayhty H, Leroy O and Eskola J: Tolerability and
immunogenicity of an 11-valent pneumococcal conjugate
vaccine in adults. Vaccine 2001, 19:1863-1869.
17. Gupta RK and Siber G: Adjuvants for human vaccines-current
status, problems and prospects. Vaccine 1995, 1995:1263-1276.
18. Clements CJ and Griffiths E: The global impact of vaccines con-
taining aluminium adjuvants. Vaccine 2002, 20:S24-33.
19. Kayhty H and Ahman H: Bridging phase 2 and phase 3 pneumo-
coccal immunologic data for future combination vaccines.
Clin Infect Dis 2001, 33:S292-298.
20. Obaro SK, Huo Z, Banya WA, Henderson DC, Monteil MA, Leach A
and Greenwood BM: A glycoprotein pneumococcal conjugate
vaccine primes for antibody responses to a pneumococcal
polysaccharide vaccine in Gambian children. Pediatr Infect Dis J
1997, 16:1135-1140.
21. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J and Eskola J:
Streptococcus pneumoniae capsular polysaccharide-diph-
theria toxoid conjugate vaccine is immunogenic in early
infancy and able to induce immunologic memory. Pediatr Infect
Dis J 1998, 17:211-216.
22. Klugman K: Efficacy of pneumococcal conjugate vaccines and
their effect on carriage and antimicrobial resistance. The Lan-
cet Infectious Diseases 2001, 1:85-91.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/3/17/prepub